JCCT 167

Shingles (also known as herpes zoster) is a painful skin rash caused by varicella zoster virus (VZV), the virus that causes chickenpox. Shingles can develop in people years after they had chickenpox. Around 1 in 3 people will develop shingles during their lifetime. The risk of developing shingles is highest in older adults.

Although there are licensed vaccines available to help prevent shingles, these vaccines may have some limitations. For example, some of the licensed vaccines may not be widely available in some countries or may have more side effects than seen with other vaccines that are given to adults.

The purpose of this study is to see if a new type of investigational VZV vaccine, called Varicella Zoster Virus modRNA Vaccine (VZV modRNA vaccine), is safe and can prompt the body to produce antibodies which may help prevent shingles. The term “investigational vaccine” means that it has not yet been approved by health authorities. As VZV modRNA vaccine is an investigational vaccine, we need to test 3 different candidates or versions of VZV modRNA vaccine to find out which candidate, dose level (strength) and dosing schedule will work best. The safety and tolerability information about the vaccine used in this study, meaning the type and frequency of any possible side effects, will be collected and evaluated throughout the study.